Triple
T22690612
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | BTK |
E561038
|
entity |
| Predicate | inhibitedBy |
P37861
|
FINISHED |
| Object | pirtobrutinib |
—
|
NE NERFINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: pirtobrutinib | Statement: [BTK, inhibitedBy, pirtobrutinib]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: pirtobrutinib Context triple: [BTK, inhibitedBy, pirtobrutinib]
-
A.
pirtobrutinib
chosen
Pirtobrutinib is a highly selective, non-covalent Bruton tyrosine kinase inhibitor used as a targeted therapy for certain B-cell malignancies.
-
B.
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
-
C.
selpercatinib
Selpercatinib is a targeted cancer therapy drug that selectively inhibits RET kinase to treat certain RET-altered thyroid and non-small cell lung cancers.
-
D.
neratinib
Neratinib is an oral tyrosine kinase inhibitor used primarily in the treatment of HER2-positive breast cancer, often as extended adjuvant therapy after trastuzumab.
-
E.
zanubrutinib
Zanubrutinib is a small-molecule Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69e2454d71b48190a1f80af9f82b6fcf |
completed | April 17, 2026, 2:35 p.m. |
| NER | Named-entity recognition | batch_69f1789a1fd08190bce5fa0babe695d3 |
completed | April 29, 2026, 3:18 a.m. |
Created at: April 17, 2026, 3:13 p.m.